



# BD Nexiva<sup>TM</sup>

Closed IV Catheter System—Dual Port



Helping all people  
live healthy lives

Four challenges you face in IV therapy today.  
And the one catheter you must have to help you meet them all.



## Catheter movement or dislodgement can lead to phlebitis and restarts.

The last thing you want to do is tell your patient you have to restart his/her IV. The BD Nexiva built-in stabilization platform is designed to minimize catheter movement and dislodgement, which may help to minimize complications and increase patient satisfaction.



## Blood exposure continues to be a risk.

Every day you're at risk of being exposed to patients' blood, which increases the likelihood of contracting a bloodborne disease. OSHA requires that employers establish a written Exposure Control Plan designed to eliminate or minimize employee exposure to bloodborne pathogens.<sup>1</sup>

The BD Nexiva all-in-one closed IV catheter system is designed to minimize blood exposure during insertion, which may reduce the potential for contamination and infection by keeping blood where it belongs—away from you.



## Clinicians are busier than ever.

You've got patients waiting and you're short on time. With BD Nexiva, there's no more locating, collecting and assembling multiple products before treating your patient. And not only is it designed to improve insertion success, the system is also capable of withstanding power injections for contrast-enhanced CT scans.\*



## Health care costs are rising rapidly.

Everyone is worried about the costs of health care. The BD Nexiva closed IV catheter system is designed to improve clinical outcomes and standardize practices, which may help lower overall hospital costs. The BD Q-Syte™ Luer Access Split Septum on the BD Nexiva eliminates the places infection-causing microorganisms may harbor.<sup>1</sup> That in itself can make a CRBSI less likely. And because treating CRBSI cases can cost more than \$103,000 per hospital stay<sup>3</sup>, taking strides to reduce that risk may be in the best interest of hospitals and patients alike.

\*24 gauge catheter system should not be used with power injectors.

# BD Nexiva™

Closed IV Catheter System—Dual Port

## Nobody understands the challenges clinicians face better than you.

The features of BD Nexiva were designed by clinicians like you to meet your needs as you care for your patients. Every feature was designed with ease of use and enhanced clinical outcomes in mind. In addition, the **BD Instaflash™ Needle Technology** is designed to reduce hit-and-miss insertion by confirming vessel entry, enabling you to stay focused on the insertion site. Clinically-proven **BD Vialon™ Biomaterial** has longer indwell times and softens up to 70% in the vessel, reducing the chance of mechanical phlebitis by up to 50%.<sup>4,5</sup>

### All-in-One Closed System

The pre-assembled system creates a closed fluid path, designed to minimize blood leakage from the catheter hub, and minimize the potential for contamination and exposure to blood.

### Built-in Stabilization Platform

The built-in stabilization platform is soft and flexible, and is designed to help minimize catheter movement in the vessel which may improve catheter dwell time.

### High-pressure Extension Set

Pre-attached high-pressure extension set is capable of power injections for contrast-enhanced CT scans.\* This preassembled system is designed to withstand pressures up to a maximum of 300 PSI.

### BD Q-Syte™ Luer Access Split Septum

A split-septum needleless access system has 64%-70% lower CRBSI rates than mechanical valves.<sup>6,7</sup> Patients are three times more likely, on average, to develop a CRBSI with the use of a mechanical valve versus a split-septum needleless access system.<sup>6,7</sup>



# BD Nexiva™ Closed IV Catheter System—Dual Port

REFERENCE NUMBER	COLOR CODE	GAUGE SIZE	CATHETER LENGTH (in)	CATHETER O.D. (mm)*	CATHETER I.D. (mm)*	EXTENSION TUBE I.D. (mm)	UNITS BOX/CASE	FLOW RATE H <sub>2</sub> O (mL/hr)
383530	Yellow	24	0.56	0.71	0.53	1.22	20/80	840
383531	Yellow	24	0.75	0.71	0.53	1.22	20/80	780
383532	Blue	22	1.00	0.90	0.67	1.22	20/80	1620
383536	Pink	20	1.00	1.10	0.83	1.65	20/80	3240
383537	Pink	20	1.25	1.10	0.83	1.65	20/80	3120
383538	Pink	20	1.75	1.10	0.83	1.65	20/80	2880
383539	Green	18	1.25	1.31	0.98	1.65	20/80	5040
383540	Green	18	1.75	1.31	0.98	1.65	20/80	4680

For power injection use, refer to Instructions For Use.

\*Average dimension.

## BD Q-Syte™ Luer Access Split Septum

REFERENCE NUMBER	UNITS BOX/CASE	FLOW RATE H <sub>2</sub> O (mL/hr)	INTERNAL VOLUME (mL)
385100	50/200	32 L/hr	0.1 mL

Test Method: ISO 10555-5 Annex B (Max flow @ 525 +/-25mL/min).



Manufactured with 100%  
Certified Renewable Energy

For more information on BD Nexiva Closed IV Catheter System please visit [www.bd.com/nexiva](http://www.bd.com/nexiva) or call us at 1.888.237.2762.



**BD Medical**  
9450 South State Street  
Sandy, Utah 84070  
1.888.237.2762  
[www.bd.com/Nexiva](http://www.bd.com/Nexiva)

<sup>1</sup> OSHA Fact Sheet. (2002). Title 29 of the Code of Federal Regulations 1910.1030.

<sup>2</sup> Karchmer TB, Wood C, Ohl CA, et al. Contamination of mechanical valve needleless devices may contribute to catheter-related bloodstream infections. SHEA 2006 Presentation Number: 221 Poster Board Number: 47.

<sup>3</sup> Centers for Medicare & Medicaid Services. (2008, April 14) CMS proposes additions to list of hospital-acquired conditions for fiscal year 2009. Available at: [www.cms.hhs.gov/apps/media/fact\\_sheets.asp](http://www.cms.hhs.gov/apps/media/fact_sheets.asp)

<sup>4</sup> Maki D, Ringer, M. Risk factors for infusion-related phlebitis with small peripheral venous catheters. *Annals of Internal Medicine*. 1991;114:845-854.

<sup>5</sup> Data on file.

<sup>6</sup> Salgado CD, et al. Increased rate of catheter-related bloodstream infection associated with use of a needleless mechanical valve device at a long-term acute care hospital. *Infection Control and Hospital Epidemiology*. 2007;28.

<sup>7</sup> Rupp ME, et al. Outbreak of bloodstream infection temporally associated with the use of an intravascular needleless valve. *Clinical Infectious Diseases*. 2007;44.